EU Commission opens antitrust probe into Sanofi's flu vaccine campaign
EU Commission opens antitrust probe into Sanofi's flu vaccine campaign BRUSSELS, June 26 (Reuters) - The European Commission opened on Friday an investigation into whether French drug giant Sanofi SASY.PA breached EU competition rules in a flu vaccine marketing campaign.
The Commission said it was concerned that Sanofi had carried out a misleading campaign to sell its "Efluelda" flu vaccine while disparaging a rival one called "Fluad" made by CSL Seqirus CSL.AX, primarily in France and Germany.
In both markets, Sanofi holds a dominant position, the Commission added.
The opening of the investigation follows unannounced raids on Sanofi offices carried out in September 2025.
At that time, had said it is confident that it was compliant with the relevant rules and regulations and would cooperate fully with the European Commission.
(Reporting by Inti Landauro;
Editing by Sudip Kar-Gupta)
Recent news on Sanofi SA
See all newsEdenTree fund manager Hiorns has bought up French stocks despite civil unrest (updated)
Early US flu season, current strain may signal risk for younger people; doctors urge shots
Brief: Sanofi Starts Work On Insulin Facility In Germany
RCS - Accession Theraptcs. - Accession Therapeutics: Board appointments
Europe Research Roundup: AJ Bell, CMC Markets, Nestle